CCCC
C4 Therapeutics, Inc.
A biopharmaceutical company developing targeted protein degradation medicines, a technology that harnesses the body's own protein-disposal machinery to destroy disease-causing proteins. Its lead programs target cancers and other serious diseases. The company was founded in 2015 as a spinout from Dana-Farber Cancer Institute, and its name reflects its focus on the "C4" family of E3 ligase enzymes that tag proteins for destruction.
CUSIP: 12529R107HealthcareUS1 holder
Total Value
$4.42M
Total Shares
2.38M
Net Share Change
+2.07M
Activity
1 buying
Investor
Value
Shares
Weight
Change
